RxDoctor Payments Data

Anthony Jackson, MD

Child & Adolescent Psychiatry · Memphis, TNNPI 1154477453

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 37 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 45.2% of the total. 2025 is the largest year on record at $459, 8.7 times the $53 reported in 2022.

$771in general payments, 2019–2025

Across 37 payments — averaging $20.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$348
  • Johnson & Johnson$216
  • Teva Pharmaceuticals USA, Inc.$50
  • Vanda Pharmaceuticals Inc.$47
  • Otsuka America Pharmaceutical, Inc.$46
  • Indivior Inc.$36
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$771100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$771 in reported general payments places this provider in the 70th percentile of 43 child & adolescent psychiatry providers in Tennessee.

See all child & adolescent psychiatry providers in Tennessee

Medicare billing

Part B allowed, 2024
$4,006
Medicare patients
19
Services billed
42

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate35$106,299
Abilify MaintenaAripiprazole28$74,250
Fluphenazine Hcl26$8,426
Aripiprazole83$3,042
Clozapine38$2,659
Ziprasidone Hcl34$1,974
Haloperidol Decanoate35$1,848
Chlorpromazine Hcl12$1,716
Divalproex Sodium68$1,516
Quetiapine Fumarate122$1,428
Benztropine Mesylate122$1,111
Olanzapine49$1,091
Haloperidol70$1,087
Trazodone Hcl147$998
Buspirone Hcl100$975

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$216$106,29935 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$46$74,25028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 43 child & adolescent psychiatry providers in Tennessee.

Other child & adolescent psychiatry in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →